Linrodostat mesylate is under clinical development by Bristol-Myers Squibb and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Linrodostat mesylate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Linrodostat mesylate overview
Linrodostat mesylate is under development for the treatment of endometrial carcinosarcoma, cutaneous melanoma, non-muscle invasive bladder cancer (NMIBC), advanced malignancy, muscle-invasive bladder cancer, non-small cell lung cancer, advanced solid tumors such as Esophageal cancer, Adenocarcinoma Of The Gastroesophageal Junction, metastatic hepatocellular carcinoma, advanced gastric cancer, advanced renal cell carcinoma and hematological tumor. It is administered orally as a capsule or a film-coated tablet. The drug candidate acts by targeting IDO1. It was also under development for the treatment of previously untreated metastatic melanoma, recurrent/metastatic head and neck squamous cell carcinoma and squamous or non-squamous non-small cell lung cancer, bladder cancer and cervical cancer.
Bristol-Myers Squibb overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
For a complete picture of Linrodostat mesylate’s drug-specific PTSR and LoA scores, buy the report here.